Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TRAW
TRAWS PHARMA, INC.
NASDAQ
$0.59
▲ UP 0.77% (0.00)

KEY STATISTICS

Market Cap$8.98 M
52w High$3.27
52w Low$0.43
Dividend Yield—
Frequency—
P/E-0.48
Volume42.21K
Shares Out.15.23M

COMPANY

LEADERSHIP

Iain D. Dukes
CHIEF EXECUTIVE
Iain D. Dukes

COMPENSATION 2026

Salary$445,769
Stock Awards$200,000
Incentive Plan Pay$0
All Other Comp.$1,813
Total$647,582

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 25, 2013
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
7

PRICE TARGET

Target High$1.00
Target Low$1.00
Target Median$1.00
Target Consensus$1.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$2.71M
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2024-09-23Reverse1:25
2021-05-21Reverse1:15
2018-09-26Reverse1:15
2016-06-01Reverse1:10

PRICE

$0.59 ▲ UP 0.77% (+$0.00)
OVERLAYS
$0.58$0.58$0.5910:12 AM11:10 AM12:08 PM1:05 PM2:03 PM3:01 PM3:59 PM0.59

About Traws Pharma, Inc.

https://www.trawspharma.com ↗

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, including COVID-19, influenza, and various cancers.

INDUSTRY

Biotechnology

A PRODUCT TRAWS PHARMA, INC. IS KNOWN FOR

Ratutrelvir
Ratutrelvir

Ratutrelvir is an investigational, ritonavir-free oral COVID-19 protease inhibitor showing promising Phase 2 results with fewer side effects and no viral rebounds, offering a potential advance for patients unsuitable for ritonavir-boosted treatments.

COMPETITORS

COMPETITOR
AVIR COMPARE
ENTA COMPARE
GILD COMPARE
MRK COMPARE
PFE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 542.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
21.34%
HOLDERS
36
TOP 12 OF 36 · RANKED BY POSITION SIZE
Adage Capital Partners Gp, L.L.C.
730.0K sh · $1.34M
Ikarian Capital, LLC
678.1K sh · $1.24M
Orbimed Advisors LLC
605.5K sh · $684.25K
Dauntless Investment Group, LLC
417.0K sh · $763.11K
Boothbay Fund Management, LLC
194.5K sh · $356K
Adar1 Capital Management, LLC
154.4K sh · $174.51K
Vestal Point Capital, LP
150.0K sh · $277.5K
Vanguard Group Inc
87.3K sh · $98.6K
Geode Capital Management, LLC
77.1K sh · $141.1K
Palumbo Wealth Management LLC
61.2K sh · $111.95K
Alyeska Investment Group, L.P.
52.6K sh · $77.89K
Xtx Topco Ltd
42.2K sh · $47.7K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF SCIENCE OFFICER VIROLOGY
Pauza Charles David
Purchase · 97.0K shares
2026-07-09
★
DIRECTOR, OFFICER: CHIEF OPERATING OFFICER
Savchuk Nikolay
Purchase · 93.0K shares
2026-07-09
★
DIRECTOR
CAUTREELS WERNER
Purchase · 14.2K shares
2026-07-09
★
DIRECTOR
STOVER JACK E
Purchase · 14.2K shares
2026-07-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 2
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL Ladenburg Thalmann NEUTRAL

SECTORS PEERS

PEERPRICE
DWTX$2.65COMPARE
CING$5.33COMPARE
COCP$1.10COMPARE
IMRN$1.15COMPARE
BOLT$3.81COMPARE
IMNN$1.60COMPARE
BRTX$0.20COMPARE
EVGN$0.55COMPARE